ClinicalTrials.gg
CompletedNCT05486949Updated Feb 1, 2023

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

A Phase 1 interventional study of AZD4205 and carbamazepine and AZD4205 and itraconazole in Healthy Subjects, sponsored by Dizal Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of AZD4205 in healthy adult subjects (Part A) and to assess the effect of multiple doses of carbamazepine, a CYP3A4 inducer, on the single dose PK of AZD4205 in healthy adult subjects (Part B).

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to participate in the study, give written , and comply with the study restrictions.
  2. Sex: male or female; females may be of , of nonchildbearing potential, or .
  3. Age: 18 to 55 years, inclusive, at screening.
  4. (BMI): 18.0 to 30.0 kg/m2, inclusive, at screening.
  5. Weight: ≥55 kg for males and ≥45 kg for females at screening.
  6. Status: healthy subjects.
  7. Healthy status as defined by the absence of evidence of any , in the opinion of the investigator, active, or chronic disease.
  8. Ability and willingness to abstain from alcohol-, caffeine-, and methylxanthine containing beverages or food from 72 hours (3 days) prior to admission until discharge from the clinical facility.
  9. No clinically significant hematological or coagulation abnormalities, as judged by the investigator.
  10. Male subjects and female subjects of childbearing potential must agree to use protocol specified methods of and comply with pregnancy precautions as described in the protocol.
  11. All prescription medications must have been stopped at least 28 days or 5 half lives, if known prior to the admission to the clinical research center.
  12. All over the counter medication must have been stopped at least 14 days or 5 half-lives, prior to the admission to the clinical research center.
  13. Normal baseline ( \<450 msec, PR \<220 msec).
  14. Adequate organ function, defined by the absence of any clinically significant abnormalities, as judged by the investigator, of the relevant baseline clinical safety assessments.

Exclusion criteria

Exclusion Criteria:

  1. Employee of PRA or the sponsor.
  2. Any condition which, in the opinion of the investigator, would interfere with the subject's ability to provide , comply with study instructions, confound interpretation of study results, or endanger the subject if he or she takes part in the trial.
  3. Women who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 30 days after the last dose of study drug.
  4. For all females of : positive pregnancy test at screening or at admission to the clinic.
  5. Males with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after the last dose of study drug.
  6. Use of any drug or device within 30 days, or investigational biologics within 120 days before the first dose of study drug.
  7. Any disease which, in the opinion of the investigator, poses an unacceptable risk to the subject.
  8. issues of visual function as determined from the medical history and physical exams, as judged by the investigator.
  9. Clinically significant history of any drug sensitivity, drug allergy, or food allergy, as determined by the investigator.
  10. History of allergy or to AZD4205, or other drugs similar in class or similar in chemical structure to AZD4205, as judged by the investigator.
  11. History of major surgery or blood transfusion within 30 days prior to the first drug administration.
  12. History of of any type.
  13. Evidence of clinically significant or relevant renal, hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  14. Manifestation of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or any other reason that may affect the absorption of AZD4205.
  15. Positive result from a COVID-19 test per site policy and requirement.
  16. Positive test result for alcohol and/or drugs of abuse at screening or on Day -1.
  17. Positive test result from Quantiferon-TB Gold test.
  18. Presence of pulmonary infections or other clinically significant active infection within 30 days of informed consent.
  19. Received COVID-19 vaccine or any within 4 weeks prior to the first dose of the investigational medicinal product.
  20. Self-reported substance abuse within 12 months of screening.
  21. Using tobacco or nicotine products within 90 days prior to the first drug administration.
  22. Strenuous activity, sunbathing, and contact sports within 48 hours prior to admission to the clinical facility through follow-up.
  23. History of donation of more than 500 mL of blood within 60 days prior to dosing in the clinical research center or planned donation before 30 days has elapsed since intake of study drug.
  24. Plasma or donation within 7 days of dosing and through follow-up.
  25. History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average.
  26. Positive screening test for surface antigen (HBsAg), virus (HCV) antibodies, or 1 and 2 antibodies.
  27. Consumption of any nutrients/foods known to modulate CYP450 enzyme activity within 7 days prior to administration of study drug and during the study.
  28. Abnormal echocardiogram (ECHO) at baseline, as judged by the investigator.
  29. History of allergy, severe adverse reaction, intolerance, or hypersensitivity to itraconazole or other azole antifungals, as determined by the investigator (Part A Only).
  30. History of allergy, severe adverse reaction, intolerance, or hypersensitivity to carbamazepine, carboxamide derivatives, or other drugs that are structurally related to carbamazepine, as judged by the investigator (Part B Only).
  31. Individuals who have Asian ancestry (including those who have 1 or more Asian grandparent, Part B Only).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    AZD4205 and carbamazepine

    Subjects in arm 1 will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.

    Drug: AZD4205 and carbamazepine

  • Experimental
    AZD4205 and itraconazole

    Subjects in arm 2 will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.

    Drug: AZD4205 and itraconazole

Interventions

  • DrugAZD4205 and carbamazepine

    Drug pages: Golidocitinib · Carbamazepine

    All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.

  • DrugAZD4205 and itraconazole

    Drug pages: Golidocitinib · Itraconazole

    All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of AZD4205 when dosed alone or coadministered with itraconazole (Part A)

    Time frame: up to 10 days after study drug administration when AZD4205 dosed alone; up to 18 days after study drug administration when coadministered with itraconazole

  2. Time to reach maximum plasma concentration (tmax) of AZD4205 when dosed alone or coadministered with itraconazole (Part A)

    Time frame: up to 10 days after study drug administration when AZD4205 dosed alone; up to 18 days after study drug administration when coadministered with itraconazole

  3. Area under the concentration-time curve from time 0 to time of last quantifiable concentration (AUC0-t) when dosed alone or coadministered with itraconazole (Part A)

    Time frame: up to 10 days after study drug administration when AZD4205 dosed alone; up to 18 days after study drug administration when coadministered with itraconazole

  4. Area under the concentration-time curve from time 0 to infinity (AUC0-inf) when dosed alone or coadministered with itraconazole (Part A)

    Time frame: up to 10 days after study drug administration when AZD4205 dosed alone; up to 18 days after study drug administration when coadministered with itraconazole

  5. Maximum plasma concentration (Cmax) of AZD4205 when dosed alone or coadministered with carbamazepine (Part B)

    Time frame: up to 10 days after study drug administration

  6. Time to reach maximum plasma concentration (tmax) of AZD4205 when dosed alone or coadministered with carbamazepine (Part B)

    Time frame: up to 10 days after study drug administration

  7. Area under the concentration-time curve from time 0 to time of last quantifiable concentration (AUC0-t) when dosed alone or coadministered with carbamazepine (Part B)

    Time frame: up to 10 days after study drug administration

  8. Area under the concentration-time curve from time 0 to infinity (AUC0-inf) when dosed alone or coadministered with carbamazepine (Part B)

    Time frame: up to 10 days after study drug administration

07

Study locations

1 site
  • Pharmaceutical Research Associates, Inc.
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Oct 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2022
First posted
Aug 4, 2022
StartActual
Jul 27, 2022
Primary completionActual
Oct 8, 2022
CompletionActual
Oct 11, 2022
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05486949
Responsible party
Sponsor
First posted
Aug 4, 2022
Start date
Jul 27, 2022
Primary completion
Oct 8, 2022
Completion
Oct 11, 2022
Last update
Feb 1, 2023

Study contacts

Shirlian Xu
study director · Dizal Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Golidocitinib · Carbamazepine · Itraconazole

Start the discussion